Leiomyosarcoma of the uterus: clinicopathologic study

Area of Science:

• Gynecologic Oncology
• Pathology
• Surgical Oncology

Background:

• Uterine leiomyosarcoma is a rare and aggressive malignancy.
• Diagnosis is often delayed, impacting patient outcomes.
• Limited data exists on prognostic factors and optimal treatment strategies.

Purpose of the Study:

• To evaluate clinicopathologic features of uterine leiomyosarcoma.
• To assess treatment outcomes and prognostic indicators.
• To review the literature and compare findings.

Main Methods:

• Retrospective analysis of 32 uterine leiomyosarcoma cases over 12 years.
• Review of existing literature on uterine leiomyosarcoma.
• Evaluation of treatment modalities including hysterectomy, chemotherapy, and radiation therapy.

Main Results:

• Mean patient age was 55.5 years; mean interval from menopause to diagnosis was 6.7 years.
• Abnormal bleeding, pain, and pelvic mass were predominant symptoms.
• 5-year survival was 25%; 43.8% died within 3 years.
• Premenopausal women had a 63.6% 5-year survival rate, compared to 5.5% for postmenopausal women.
• Total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) was the most effective treatment.

Conclusions:

• Early surgical removal of the uterus is critical for improving cure rates.
• Age at diagnosis is a significant prognostic factor, with younger (premenopausal) patients faring better.
• Uterine leiomyosarcoma requires prompt diagnosis and aggressive management, ideally before it extends beyond a presumed leiomyoma.